Literature DB >> 8114756

Identification of charged residues in an N-terminal portion of the hormone-binding domain of the human estrogen receptor important in transcriptional activity of the receptor.

F Pakdel1, J C Reese, B S Katzenellenbogen.   

Abstract

We have shown that charged amino acids near C530 of the human estrogen receptor (ER) are involved in receptor discrimination between estrogen and antiestrogen. We now examine the role of charged residues, adjacent to the three other cysteines (381, 417, and 447) in the hormone-binding domain of the human ER, in the hormone-binding, DNA-binding, and transcription activation abilities of the receptor. Mutation of the one charged amino acid nearest to C381 gave a mutant receptor (E380Q) requiring two to three times less estradiol (E2) than wild type (WT) ER to achieve maximal activity and having activity in the absence of added estrogen that was 6-fold higher than that of WT receptor. The enhanced ability of this mutant to bind to estrogen response element DNA in the absence and presence of estrogen may, at least in part, explain its elevated, seemingly constitutive trans-activation activity and its increased sensitivity to estrogen. While more sensitive to E2, this E380Q mutant was less sensitive than WT ER to antiestrogen for suppression of transcriptional activity. Mutation of all three charged residues nearest to C381 (the triple mutant D374N, E380Q, and E385Q) resulted in a greatly reduced potency of the receptor in trans-activation with no change in estrogen-binding affinity. When K449 (near C447), highly conserved among steroid receptors, was mutated to Q, 400-fold more E2 was required for maximal reporter gene trans-activation due to an unstable, temperature-sensitive hormone-receptor complex. In contrast, the mutant K416Q (near C417) was unaltered in E2-binding or receptor transcriptional activity. These studies reveal a region in the N-terminal portion of the hormone-binding domain (ca. amino acids 374-385) where alterations in charged residues result in either increases or decreases in receptor transcriptional activity with no change in receptor affinity for hormone. Our findings suggest that this region may be important in DNA binding and protein-protein interactions that modulate transcriptional activity of the ER. In addition, the region near C447, which is well conserved among steroid receptors, appears to be important in maintaining the receptor in a conformation that is stable at physiological (37 C) temperatures. To our knowledge, this is the first report of an ER (E380Q) with a sensitivity to E2 for trans-activation greater than that of WT receptor and having high trans-activation activity in the absence of added hormone.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8114756     DOI: 10.1210/mend.7.11.8114756

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  16 in total

1.  Estrogen receptor mutations found in breast cancer metastases integrated with the molecular pharmacology of selective ER modulators.

Authors:  V Craig Jordan; Ramona Curpan; Philipp Y Maximov
Journal:  J Natl Cancer Inst       Date:  2015-04-02       Impact factor: 13.506

2.  Regulation of estrogen receptor α N-terminus conformation and function by peptidyl prolyl isomerase Pin1.

Authors:  Prashant Rajbhandari; Greg Finn; Natalia M Solodin; Kiran K Singarapu; Sarata C Sahu; John L Markley; Kelley J Kadunc; Stephanie J Ellison-Zelski; Anastasia Kariagina; Sandra Z Haslam; Kun Ping Lu; Elaine T Alarid
Journal:  Mol Cell Biol       Date:  2011-11-07       Impact factor: 4.272

3.  Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts.

Authors:  Shunqiang Li; Dong Shen; Jieya Shao; Robert Crowder; Wenbin Liu; Aleix Prat; Xiaping He; Shuying Liu; Jeremy Hoog; Charles Lu; Li Ding; Obi L Griffith; Christopher Miller; Dave Larson; Robert S Fulton; Michelle Harrison; Tom Mooney; Joshua F McMichael; Jingqin Luo; Yu Tao; Rodrigo Goncalves; Christopher Schlosberg; Jeffrey F Hiken; Laila Saied; Cesar Sanchez; Therese Giuntoli; Caroline Bumb; Crystal Cooper; Robert T Kitchens; Austin Lin; Chanpheng Phommaly; Sherri R Davies; Jin Zhang; Megha Shyam Kavuri; Donna McEachern; Yi Yu Dong; Cynthia Ma; Timothy Pluard; Michael Naughton; Ron Bose; Rama Suresh; Reida McDowell; Loren Michel; Rebecca Aft; William Gillanders; Katherine DeSchryver; Richard K Wilson; Shaomeng Wang; Gordon B Mills; Ana Gonzalez-Angulo; John R Edwards; Christopher Maher; Charles M Perou; Elaine R Mardis; Matthew J Ellis
Journal:  Cell Rep       Date:  2013-09-19       Impact factor: 9.423

Review 4.  Structural underpinnings of oestrogen receptor mutations in endocrine therapy resistance.

Authors:  John A Katzenellenbogen; Christopher G Mayne; Benita S Katzenellenbogen; Geoffrey L Greene; Sarat Chandarlapaty
Journal:  Nat Rev Cancer       Date:  2018-06       Impact factor: 60.716

5.  The role of calcium in the activation of estrogen receptor-alpha.

Authors:  Shailaja D Divekar; Geoffrey B Storchan; Katherine Sperle; David J Veselik; Earl Johnson; Sivanesan Dakshanamurthy; Yuse N Lajiminmuhip; Rebecca E Nakles; Li Huang; Mary Beth Martin
Journal:  Cancer Res       Date:  2011-01-06       Impact factor: 12.701

6.  AF-2 activity and recruitment of steroid receptor coactivator 1 to the estrogen receptor depend on a lysine residue conserved in nuclear receptors.

Authors:  P M Henttu; E Kalkhoven; M G Parker
Journal:  Mol Cell Biol       Date:  1997-04       Impact factor: 4.272

7.  Structurally Novel Antiestrogens Elicit Differential Responses from Constitutively Active Mutant Estrogen Receptors in Breast Cancer Cells and Tumors.

Authors:  Yuechao Zhao; Mary J Laws; Valeria Sanabria Guillen; Yvonne Ziegler; Jian Min; Abhishek Sharma; Sung Hoon Kim; David Chu; Ben Ho Park; Steffi Oesterreich; Chengjian Mao; David J Shapiro; Kendall W Nettles; John A Katzenellenbogen; Benita S Katzenellenbogen
Journal:  Cancer Res       Date:  2017-09-13       Impact factor: 12.701

8.  A hypersensitive estrogen receptor alpha mutation that alters dynamic protein interactions.

Authors:  Matthew H Herynk; Torsten Hopp; Yukun Cui; Airu Niu; Arnoldo Corona-Rodriguez; Suzanne A W Fuqua
Journal:  Breast Cancer Res Treat       Date:  2009-10-20       Impact factor: 4.872

9.  Identification of tamoxifen-induced coregulator interaction surfaces within the ligand-binding domain of estrogen receptors.

Authors:  Nina Heldring; Maria Nilsson; Benjamin Buehrer; Eckardt Treuter; Jan-Ake Gustafsson
Journal:  Mol Cell Biol       Date:  2004-04       Impact factor: 4.272

10.  The search for ESR1 mutations in breast cancer.

Authors:  Steffi Oesterreich; Nancy E Davidson
Journal:  Nat Genet       Date:  2013-12       Impact factor: 38.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.